Skip to main content

Roche

 

Clinical courses

  • Roche announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumours (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab.

  • Amgen join with Roche on a phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.

  • The US Food and Drug Administration (FDA) has approved Roche's cobas KRAS mutation test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumour samples from metastatic colorectal cancer (mCRC) patients and aid clinicians in determining a therapeutic path for them.

  • Work as Product Specialist- South, North (RMD) in Roche

    At Roche, 80,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the world’s leading research-focused healthcare groups. Our success is built on innovation, curiosity and diversity, and on seeing each other’s differences as an advantage. To innovate healthcare, Roche has ambitious plans to keep learning and growing – and is seeking people who have the same goals for themselves.

  • Liraglutide Superior to Sitagliptin When Added to Metformin for Glycemic Control

    The addition of a glucagonlike peptide-1 (GLP-1) agonist in patients with inadequate glycemic control when treated with metformin alone resulted in significantly larger reductions in HbA1c levels when compared with the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor, a new study has shown.

Subscribe to Roche